product and service
continuous experimentation!
Why we are here?
What we believe in?
Being
empathetic
Invent and pioneer
for human well being
Excellence in
everything we do
Working
together
Improving planet
sustainability
Being honest and
consistent
What we want to be?
The Clear Choice
Our customer value
associating with us
Our people want to
invest their careers with us
Our communities
trust us
How will we reach there?
Our Promise
Our journey
The secret of a bright future is crafted in the womb of history!
Started R&D and ramped up with 120 people with strong IPR team
2015Acquisition of Laurel Organics limited, a listed company in 2016.
2016Accreditation of who GMP in 2019 and DSIR R&D in 2017.
2017Filed KDMF for 2 key products, Benfotiamine and Fimasartan Potassium Hydrochloride.
2017Commenced export business in Pakistan 2017 and quickly ramped up exports to more than 15 countries between 2018-2020 and successfully exported to the US in 2021.
2017Upgraded facility with 2 modern Microbiology labs, Water System, 5 clean room and In house micronization.
2018Ramped up exports to more than 15 countries
2018-20Started nutraceutical exports to the U.S.
Developed DCGI-approved APIs; first- and second-time launches in India.
Gained approvals in South Africa, Taiwan.
Business expanded into LATAM & Asia-Pacific.
Launched products in China; filed products in EU.
Filed multiple patents.
Team
Mr. Sameer Goel
Managing Director (MD)
Mr. Sameer Goel is the Managing Director and heading Kimia Biosciences. He holds a tall stature in the Indian API market and has strong multi-dimensional capabilities in the areas of Business Development, Product Development, Strategic Marketing and Operations Management. He has played a key leadership role with various organizations in acquiring and aligning the strong support of professional networks, business partners and executive teams to accomplish expertise in manufacturing, sales, marketing and trading of various APIs and its Intermediates.
Currently, Mr. Goel is responsible for providing overall leadership in achieving business & product development goals and formation of strategic partnerships in Business.
Mr. M.R.V. 'PRASADA Raju
Chief Operating Officer (COO)
Mr. Raju is a Postgraduate in Organic Chemistry with over 35 years of experience in the pharmaceutical industry. He has worked with several leading Indian MNCs, gaining extensive expertise in end-to-end manufacturing, establishing and managing profit-center-based business units, and overseeing strategic operations.
He founded Mantena Laboratories Ltd., setting up R&D and manufacturing facilities with stringent quality standards to meet global regulatory requirements, including USFDA compliance. Known for his commitment to completing projects on time and within budget, Mr. Raju has successfully developed and commercialized new processes and products, achieving significant international growth.
He has built strong relationships with major MNCs across Europe and the USA, consistently leading sales promotions and establishing a strong global presence through a decade of successful exhibitions in various European countries.
Dr. Rita Sarin
Dr. Rita Sarin is an Advisor and heading IPR and Strategic Management at Kimia Biosciences Ltd. She is Ph.D. degree in Medicinal Chemistry from Central Drug Research Institute (CDRI), Lucknow and has 24 years of extensive experience in various aspects of Intellectual Property. She has previously worked at Ranbaxy (now Sun Pharma) and Lupin Research Laboratories. She has received an award from the President of India, late Shri Dr. Abdul Kalam Azad in 2012 for the launch of Synriam TM, the first drug developed in India.
- Important Links
KIMIA BIOSCIENCE LIMITED
974, Aggarwal Millennium Tower II,
Netaji Subhash Place, Pitampura,
New Delhi-110 034
+91-11-4706 3600
info@kimiabiosciences.com
sales@kimiabiosciences.com
Kimia Biosciences Ltd™ is a leading manufacturer of bulk drugs focused on high-potential therapeutic segments. The company is pursuing an ambitious growth strategy driven by infrastructure expansion and Contract Development & Manufacturing (CDMO) initiatives.